ArticleClinical and experimental immunology1998
Selective depletion of CD14+ CD16+ monocytes by glucocorticoid therapy.
Article in Clinical and experimental immunology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Potential Involvement of Platelet-Derived Microparticles and Microparticles Forming Immune Complexes during Monocyte Activation in Patients with Systemic Lupus Erythematosus.Frontiers in immunology · 2018Trial
- The number of circulating monocytes as biomarkers of the clinical response to methotrexate in untreated patients with rheumatoid arthritis.Journal of translational medicine · 2015Trial
- Glucocorticoid boluses followed by tocilizumab in giant cell arteritis patients: effects on peripheral blood monocytes and lymphocytes.Frontiers in immunology · 2025Article
- Comparative Analysis of Fcγ and Complement Receptors Presence on Monocytes in Pulmonary Sarcoidosis and Tuberculosis.International journal of molecular sciences · 2023Article
- Article
- Baricitinib therapy response in rheumatoid arthritis patients associates to STAT1 phosphorylation in monocytes.Frontiers in immunology · 2022Article
- Laquinimod dampens IL-1β signaling and Th17-polarizing capacity of monocytes in patients with MS.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- Effect of Kidney Transplantation on Accelerated Immunosenescence and Vascular Changes Induced by Chronic Kidney Disease.Frontiers in medicine · 2021Article
- Biomarkers in the Diagnosis and Prognosis of Sarcoidosis: Current Use and Future Prospects.Frontiers in immunology · 2020Review
- The Roles of Monocyte and Monocyte-Derived Macrophages in Common Brain Disorders.BioMed research international · 2020Review
- Inhibiting the immunoproteasome's β5i catalytic activity affects human peripheral blood-derived immune cell viability.Pharmacology research & perspectives · 2019Article
- Inherited and Environmental Factors Influence Human Monocyte Heterogeneity.Frontiers in immunology · 2019Review
- 6-Sulfo LacNAc (Slan) as a Marker for Non-classical Monocytes.Frontiers in immunology · 2019Review
- CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia.International journal of hematology · 2018Article
- The pro-inflammatory phenotype of the human non-classical monocyte subset is attributed to senescence.Cell death & disease · 2018Article
- Circulatory Immune Cells in Cushing Syndrome: Bystanders or Active Contributors to Atherometabolic Injury? A Study of Adhesion and Activation of Cell Surface Markers.International journal of endocrinology · 2017Article
- Analysis of PD-1 expression in the monocyte subsets from non-septic and septic preterm neonates.PloS one · 2017Article
- Role of monocytes and macrophages in regulating immune response following lung transplantation.Current opinion in organ transplantation · 2016Review
- Human T Cell Leukemia Virus Type 1 Infection of the Three Monocyte Subsets Contributes to Viral Burden in Humans.Journal of virology · 2015Article
- Nonclassical patrolling monocyte function in the vasculature.Arteriosclerosis, thrombosis, and vascular biology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucocorticoids (GC) are potent anti-inflammatory and immunosuppressive agents that act on many cells of the body, including monocytes. Here we show that a 5-day course of high dose GC therapy differentially affected the CD14++ and the CD14+ CD16+ monocyte subpopulations in 10 patients treated for multiple sclerosis. While the classical (CD14++) monocytes exhibited a substantial increase from 495 +/- 132 to 755 +/- 337 cells/microl, the CD14+ CD16+ monocytes responded with a pronounced decrease from 36 +/- 15 to 2 +/- 3 cells/microl (P < 0.001). In 4/10 patients the CD14+ CD16+ monocytes fell below detection limits (<0.2 cells/microl). This observation was confirmed when the CD14+ CD16+ monocytes were identified by virtue of their low CD33 expression as these cells decreased as well. After discontinuation of GC therapy the CD14+ CD16+ monocytes reappeared and reached normal levels after 1 week. The profound depletion of CD14+ CD16+ monocytes by GC as described here is a novel effect of GC action in vivo and may contribute to GC-mediated immunosuppression. Determination of the number of this monocyte subset may also serve to monitor the effectiveness of GC therapy in patients requiring immunosuppressive treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.